Search research articles
Contact Us
Filters
Showing results (141-150 of 173) with videos related to
Page
of 18
Sort By:
Journal for Immunotherapy of Cancer
|
August 3, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 3, 2023
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
Keunchil Park, Joshua K Sabari, Eric B Haura, et al.
Cell Reports. Medicine
|
December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard, Michael S Gordon, Sunil Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2018
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn, Jeffrey R Infante, Karen L Reckamp, et al.
Cancer Research Communications
|
January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors
Jong Chul Park, David Berz, Manish R Sharma, et al.
Cancer Research Communications
|
February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Jong Chul Park, David Berz, Manish R Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer
Solange Peters, Sarina A Piha-Paul, Kartik Sehgal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Future Oncology (London, England)
|
March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 173) with videos related to
Sort By:
Page
of 18
Journal for Immunotherapy of Cancer
|
August 3, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 3, 2023
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
Keunchil Park, Joshua K Sabari, Eric B Haura, et al.
Cell Reports. Medicine
|
December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard, Michael S Gordon, Sunil Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2018
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn, Jeffrey R Infante, Karen L Reckamp, et al.
Cancer Research Communications
|
January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors
Jong Chul Park, David Berz, Manish R Sharma, et al.
Cancer Research Communications
|
February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors
Jong Chul Park, David Berz, Manish R Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer
Solange Peters, Sarina A Piha-Paul, Kartik Sehgal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Future Oncology (London, England)
|
March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Page
of 18